| 18.76 0.53 (2.91%) | 01-09 13:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.49  |
1-year : | 30.94 |
| Resists | First : | 22.68 |
Second : | 26.49 |
| Pivot price | 17.17 |
|||
| Supports | First : | 17.24 |
Second : | 13.88 |
| MAs | MA(5) : | 16.91 |
MA(20) : | 17.23 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 69.2 |
D(3) : | 52.3 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 24.03 | Low : | 13.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVMN ] has closed below upper band by 13.7%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 18.71 - 18.78 | 18.78 - 18.86 |
| Low: | 16.84 - 16.92 | 16.92 - 17 |
| Close: | 18.09 - 18.22 | 18.22 - 18.35 |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Thu, 08 Jan 2026
Evommune (NYSE:EVMN) Shares Gap Up - What's Next? - MarketBeat
Tue, 06 Jan 2026
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Tue, 06 Jan 2026
Evommune (EVMN) Receives 'Buy' Rating from HC Wainwright & Co. | - GuruFocus
Tue, 23 Dec 2025
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Mon, 22 Dec 2025
Hopfner buys Evommune (EVMN) shares worth $17,350 - Investing.com
Thu, 11 Dec 2025
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 479 (K) |
| Shares Short P.Month | 103 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -117.78 |
| Profit Margin | 0 % |
| Operating Margin | -133.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.41 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -2.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -8.94 |
| PEG Ratio | 0 |
| Price to Book value | -0.16 |
| Price to Sales | 45.29 |
| Price to Cash Flow | -7.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|